Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. STXS
STXS logo

STXS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Stereotaxis Inc (STXS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.850
1 Day change
-1.60%
52 Week Range
3.590
Analysis Updated At
2026/04/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Stereotaxis Inc (STXS) is not a strong buy at the moment for a long-term beginner investor with $50,000-$100,000 available for investment. While the company has shown revenue growth, its declining net income, EPS, and gross margin, combined with neutral trading trends and lack of significant positive catalysts, suggest a cautious approach. The technical analysis does not indicate a clear upward trend, and there are no strong trading signals or influential endorsements to support immediate investment.

Technical Analysis

The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 54.056, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting no strong upward trend. The stock is trading near its resistance level (R1: 1.921), which may limit further short-term gains.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
2

Positive Catalysts

  • Revenue increased by 36.31% YoY in Q4 2025, indicating growth in the company's top line.

Neutral/Negative Catalysts

  • Net income dropped by -25.39% YoY, EPS declined by -33.33% YoY, and gross margin fell slightly by -1.30% YoY. There are no significant trading trends from hedge funds or insiders, and no recent news or endorsements from influential figures.

Financial Performance

In Q4 2025, the company reported revenue growth of 36.31% YoY to $8.642 million. However, net income dropped to -$5.849 million (-25.39% YoY), EPS declined to -$0.06 (-33.33% YoY), and gross margin decreased slightly to 50.07% (-1.30% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for Stereotaxis Inc.

Wall Street analysts forecast STXS stock price to rise
5 Analyst Rating
Wall Street analysts forecast STXS stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.880
sliders
Low
4
Averages
4.2
High
5
Current: 1.880
sliders
Low
4
Averages
4.2
High
5
Citizens
Outperform
initiated
$4
AI Analysis
2025-12-16
Reason
Citizens
Price Target
$4
AI Analysis
2025-12-16
initiated
Outperform
Reason
Citizens initiated coverage of Stereotaxis with an Outperform rating and $4 price target. Stereotaxis develops robotic platforms for use in endovascular surgeries, the analyst tells investors in a research note. The firm views the company as a "unique micro-cap MedTech name worth owning" due to its key product developments set to be tailwinds for system adoption and improved procedural utilization through 2026.
Roth Capital
NULL
to
Buy
initiated
$4
2025-11-05
Reason
Roth Capital
Price Target
$4
2025-11-05
initiated
NULL
to
Buy
Reason
Roth Capital resumed coverage of Stereotaxis with a Buy rating and $4 price target. The firm believes the company is positioned for long-term revenue growth and profitability from continued adoption of its Robotic Magnetic Navigation technology along with "imminent" regulatory approvals and subsequent commercial launches of its product pipeline.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for STXS
Unlock Now

People Also Watch